CHICAGO / Mar 14, 2023 / Business Wire / Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.
Veradigm Practice Management placed in the top five practice management solutions across all physician group size categories, including:
Veradigm Practice Management is a comprehensive revenue cycle management solution for physician practices of all sizes and specialties. With over 20 years’ experience, Veradigm Practice Management is an EHR-agnostic solution that streamlines every step along the revenue cycle, from pre-appointment to final collections and data analysis.
“With best-in-class solutions like Veradigm Practice Management, we are supporting healthcare providers to optimize revenue, manage their day-to-day operations, engage in productive patient interactions, and save staff time,” said Tom Langan, President and Chief Commercial Officer of Veradigm. “This ranking demonstrates our continued commitment to help deliver a higher quality of care, more economically.”
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit http://www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube
© 2023 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Last Trade: | US$4.65 |
Daily Change: | -0.05 -1.06 |
Daily Volume: | 9,450 |
Market Cap: | US$504.990M |
February 27, 2024 February 22, 2024 January 10, 2024 January 09, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load